An historical cohort mortality study of research and development personnel (primarily chemists) actively employed on Dec 31, 1961, with at least 1 year of service with the Allied Corporation was carried out. These employees experienced lower mortality for all causes of death combined and all cancer causes combined than would be expected on the basis of the general US population. The degree of deficit in all causes of death combined was below the healthy worker effect usually associated with occupational mortality studies of production workers. There was one statistically significant excess, that for cancer of the prostate among research laboratory personnel who worked during the period 1945 to 1955, a period during which researchers may have been exposed to insecticides or fluorine derivatives. Substantial deficits were observed for causes of death known to be related to life-style, suggesting that mortality among Allied's salaried employees, including research and development workers, may have been influenced more by these factors than by occupational factors.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term survival of participants in the PASART-1 and PASART-2 trials of neo-adjuvant pazopanib and radiotherapy in soft tissue sarcoma.
Acta Oncol
January 2025
Department of Radiotherapy, the Netherlands Cancer Institute, Amsterdam, the Netherlands: Department of Radiotherapy, Leiden University Medical Center, Leiden, the
Objective: This study aims to assess the long-term safety and efficacy of adding pazopanib to neo-adjuvant radiotherapy followed by surgery in patients with high-risk non-metastatic soft tissue sarcoma of the trunk and extremities treated in the PASART-1 and PASART-2 trials, as well as to compare the PASART cohorts to a control cohort receiving standard treatment during the same time period from the Netherlands Cancer Registry (IKNL) to investigate if adding pazopanib improves Overall Survival (OS).
Methods: Updated follow-up data on disease control, survival and long-term toxicities of the PASART-trials were extracted from electronic patient records. The effect of adding pazopanib to neo-adjuvant radiotherapy on OS was investigated by comparing the combined PASART cohorts to the IKNL cohort via direct comparison and exact matching analysis.
Effects of population aging on quality of life and disease burden: a population-based study.
Glob Health Res Policy
January 2025
Center for Public Health and Epidemic Preparedness and Response, Peking University, Haidian District, 38Th Xueyuan Road, Beijing, 100191, China.
Background: As population aging intensifies, it becomes increasingly important to elucidate the casual relationship between aging and changes in population health. Therefore, our study proposed to develop a systematic attribution framework to comprehensively evaluate the health impacts of population aging.
Methods: We used health-adjusted life expectancy (HALE) to measure quality of life and disability-adjusted life years (DALY) to quantify the burden of disease for the population of Guangzhou.
Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using FDG and Cu-DOTA-Trastuzumab Positron Emission Tomography Studies.
JCO Clin Cancer Inform
January 2025
SimBioSys Inc, Chicago, IL.
Purpose: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers.
Methods: Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency.
Impact of Non-Hepatectomy Opioid Reduction Efforts on Post-Hepatectomy Opioid Prescriptions: Analysis of 2,005 Patients.
J Am Coll Surg
January 2025
Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Introduction: Pathway-driven, post-pancreatectomy opioid reduction interventions have proven effective and sustainable and may have a "halo effect" on other major abdominal cancer operations. This study's aim was to analyze the sequential effects of expanding opioid reduction efforts from pancreatectomy on opioids prescribed after hepatectomy.
Methods: This is a retrospective cohort study utilizing data from the electronic health record and a prospective quality improvement database for consecutive hepatectomy patients (09/2016-02/2024).
Impact of the COVID-19 pandemic on primary care for hypertension in the UK: a population-based cohort study.
BMJ Open
December 2024
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada
Objectives: To describe the impact of the COVID-19 pandemic on hypertension diagnosis and management in UK primary care.
Design: Population-based cohort study.
Setting: Over 2000 general practices across the UK contributing to the Clinical Practice Research Datalink.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!